Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000020295 | SCV004276153 | likely pathogenic | UDPglucose-4-epimerase deficiency | 2023-10-05 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 302 of the GALE protein (p.Gly302Asp). This variant is present in population databases (rs137853861, gnomAD 0.02%). This missense change has been observed in individual(s) with galactose epimerase deficiency (PMID: 16301867). ClinVar contains an entry for this variant (Variation ID: 21173). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALE protein function. Experimental studies have shown that this missense change affects GALE function (PMID: 19250319). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Gene |
RCV000020295 | SCV000040660 | not provided | UDPglucose-4-epimerase deficiency | no assertion provided | literature only | Account for 67% of alleles reported in a cohort of asymptomatic Koreans with peripheral epimerase deficiency galactosemia |